Ser503
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser503  -  REL (human)

Site Information
VNMMTTSsDSMGETD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 453447

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 )
Disease tissue studied:
ataxia-telangiectasic cancer ( 1 )
Relevant cell line - cell type - tissue:
Jurkat (T lymphocyte) ( 2 ) , spleen ( 1 )

Downstream Regulation
Effects of modification on biological processes:
apoptosis, inhibited ( 2 ) , transcription, altered ( 1 ) , transcription, induced ( 2 )

References 

1

Starczynowski DT, Reynolds JG, Gilmore TD (2005) Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability. Oncogene 24, 7355-68
16027730   Curated Info

2

Martin AG, Fresno M (2000) Tumor necrosis factor-alpha activation of NF-kappa B requires the phosphorylation of Ser-471 in the transactivation domain of c-Rel. J Biol Chem 275, 24383-91
10823840   Curated Info